WISER After Ovarian Cancer - Exercise Pilot Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Ovarian Cancer
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Number of adverse events
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
One in four deaths in the United States is due to cancer, and one in three women will develop cancer in her lifetime. Despite improvements in survival among other forms of cancer, ovarian cancer prognosis remains poor. Eighty percent of women with ovarian cancer will present with advanced disease (stage 3 or 4) where 5-year survival ranges from 18-34%.2 Among patients with stage III and IV epithelial ovarian cancer (EOC), recurrence rates are high.4 Therefore, interventions focused on preventing recurrence or slowing progression of EOC is a critical problem in the field. The investigators have submitted an R21 to NCI for a dose response exercise intervention trial to examine the dose response effects of aerobic exercise on biomarkers relevant to ovarian cancer progression and recurrence. The reviewers would like assurance that the investigators can recruit ovarian cancer patients into an exercise study and that these women will do the exercise protocol we plan to prescribe in our high dose of exercise.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of stage III-IV EOC, completed surgery,
- •\> 12 months life expectancy (physician estimate),
- •able to walk 15 minutes at a time (use of a cane is acceptable).
Exclusion Criteria
- •medical or psychiatric conditions (beyond ovarian cancer, its treatment, and its symptoms) that would impair our ability to test study hypotheses (e.g. cardiac, pulmonary, or
- •orthopedic history that would prohibit a program of walking for exercise;
- •psychotic disorders,
- •dementia,
- •inability to give informed consent
Outcomes
Primary Outcomes
Number of adverse events
Time Frame: 26 weeks